Seven children with Fanconi anaemia (FA) (five female, two male), who had not undergone transformation, received nine haemopoietic stem cell transplantation (HSCT) between 2000 and 2004. Conditioning regimen was: fludarabine 25-30 mg/m 2 /day for 5 days, antilymphocyte globulin 12.5 mg/kg/day for 3 days and cyclophosphamide 5-7.5 mg/kg/day for 4 days. Radiation was not used. One male patient who had multiple HSCT and one female who was retransplanted, received slightly different conditioning regimens. Four patients received fully matched unrelated umbilical cord blood (UCB), two matched unrelated peripheral blood stem cell (PBSC) grafts, and three haploidentical T-cell-depleted (TCD) PBSC grafts. None of the patients had any significant conditioning-related toxicity or severe infections. All engrafted within 2-3 weeks. One patient rejected her first HSCT after 10 weeks and had a second successful transplant from the same donor. One male patient rejected his TCD haploidentical HSCT from his mother, and subsequently had a successful fully matched unrelated UCB transplant. Rejection rate was 22%. Acute and chronic graft-versus-host disease (GVHD) was seen in 77 and 22% patients. In all, 57% patients developed autoimmune complications, all of which have resolved. All patients are well with stable or full donor chimerism after a median follow-up of 37 months (range 13-54 Graft rejection, a high incidence of graft-versus-host disease (GVHD) and regimen-related toxicity are the main causes of treatment failure. In the context of unrelated/ alternative HSCT, designing a suitable conditioning regimen has been difficult because of the increased sensitivity of FA cells to DNA crosslinking agents 8 and radiation. 9 Investigators are still searching for the 'ideal' preparative regimen, able to reduce the risk of organ toxicity and late side effects, while ensuring a high level of engraftment and a low risk of GVHD. The best results have been observed with cyclophosphamide (CY) 40 mg/kg, rabbit antithymocyte globulin (ATG) and low-dose total body irradiation 4.5 Gray. 4 However, even with this regimen, graft rejection and grade II-IV acute GVHD rates of 30 and 50%, respectively, have been reported. Data for transplants from related HLA-mismatched donors are scarce and the reported outcome is worse than for allografts from unrelated volunteers. 7, 10, 11 Recently, Rossi et al 12 successfully performed a T-cell-depleted (TCD) haploidentical HSCT using a fludarabine-based conditioning regimen without irradiation. Boulad et al 13 successfully transplanted a TCD-related HLA-mismatched HSCT using a fludarabine-based preparative regimen with radiation (4.5 Gray) in an FA patient who rejected her first allograft. Likewise, Elhasid et al 11 reported a 10-year-old girl who underwent a second successful HSCT from her haploidentical father after rejecting her first allograft, where her mother who was HLA mismatched was the
plantation; nonradiotherapy-based regimen
Fanconi anaemia (FA) is an autosomal recessive disorder characterized by chromosomal fragility, a variety of congenital abnormalities, progressive bone marrow failure and marked propensity to develop malignancies. 1 Haematological complications develop in virtually all cases and are the cause of death in 81% of FA patients before the age of 40 years. 2 Treatment for haematological disease in FA patients can either be supportive with blood product transfusions, anabolic steroids and haematopoietic growth factors, or curative with haemopoietic stem cell transplantation (HSCT). FA is a universally accepted indication for an HLA-identical sibling allograft and excellent results have been reported with such transplants. 3 Unfortunately, many patients with FA do not have a matched related donor (MRD). The outcome of HSCT using alternative donors is less favourable. To date, successful outcome for HSCT in FA from unrelated donors has been reported to be in the range 29-43%. 4, 5 Family members with varying degrees of HLA mismatch have been used as alternative donors with some degree of success. 6, 7 Graft rejection, a high incidence of graft-versus-host disease (GVHD) and regimen-related toxicity are the main causes of treatment failure. In the context of unrelated/ alternative HSCT, designing a suitable conditioning regimen has been difficult because of the increased sensitivity of FA cells to DNA crosslinking agents 8 and radiation. 9 Investigators are still searching for the 'ideal' preparative regimen, able to reduce the risk of organ toxicity and late side effects, while ensuring a high level of engraftment and a low risk of GVHD. The best results have been observed with cyclophosphamide (CY) 40 mg/kg, rabbit antithymocyte globulin (ATG) and low-dose total body irradiation 4.5 Gray. 4 However, even with this regimen, graft rejection and grade II-IV acute GVHD rates of 30 and 50%, respectively, have been reported. Data for transplants from related HLA-mismatched donors are scarce and the reported outcome is worse than for allografts from unrelated volunteers. 7, 10, 11 Recently, Rossi et al 12 successfully performed a T-cell-depleted (TCD) haploidentical HSCT using a fludarabine-based conditioning regimen without irradiation. Boulad et al 13 successfully transplanted a TCD-related HLA-mismatched HSCT using a fludarabine-based preparative regimen with radiation (4.5 Gray) in an FA patient who rejected her first allograft. Likewise, Elhasid et al 11 reported a 10-year-old girl who underwent a second successful HSCT from her haploidentical father after rejecting her first allograft, where her mother who was HLA mismatched was the donor. Only a limited number of patients have received unrelated umbilical cord blood (UCB) transplantation and its role is still uncertain.
14, 15 Yoshimasu et al 16 reported prompt and durable haemopoietic reconstitution by UCB transplantation in one patient. Medeiros et al 17 reported successful UCB in a 5-year-old child.
FA patients are natural candidates for reduced intensity conditioning, because of their cellular hypersensitivity to DNA crosslinking agents such as CY and radiotherapy. 18 Fludarabine-based conditioning regimens are attractive as they are capable of intense T-cell immunosuppression, and have been successfully used for various nonmalignant diseases, with minimal toxicity, stable and durable engraftment. 19, 20 We describe the outcome of seven patients with FA who received nine HSCT using alternative donors and were prepared with nonradiotherapy-based conditioning regimens.
Patients and methods

Patients
Between 2000 and 2004, seven patients with FA received a total of nine HSCT from alternative donors. In all patients, the diagnosis of FA was confirmed with mitomycin-Cinduced chromosomal breakage analysis. 21 Patient characteristics are shown in Table 1 . Age at transplant ranged from 5 to 10 years. Five patients had moderate aplastic anaemia (MAA), and two severe aplastic anaemia (SAA). No patients had myelodysplastic syndrome or leukaemic transformation. Prior treatment consisted of erythrocyte and platelet transfusions. In one patient androgen therapy was used. Chromosomal analysis showed normal karyotypes in all patients. Bone marrow cytology pre-HSCT was hypoplastic in all patients (Table 1) .
Donor selection
Donor searches were made and as far as possible HLA A, B, Cw and DR identical donors were selected and retyped using polymerase chain reaction-sequence-specific primer (PCR-SSP).
Details of donor age, sex and HLA matching are shown in Table 2 .
Transplant procedure
Details of the transplant procedure are shown in Table 3 .
All patients received conditioning regimen as shown in Table 3 : fludarabine 25-30 mg/m 2 /day for 5 days, antilymphocyte globulin 12.5 mg/kg/day for 3 days and CY 5-7.5 mg/kg/day for 4 days. Radiation was not used for any patient. Patient 1 had slightly different conditioning therapy when re-transplanted (1B) following rejection of her first graft. The details for patient 3 represent his 3rd and 4th grafts -he had rejected two previous single mismatched related grafts. Cyclosporin was used as GVHD prophylaxis at a dose of 2.5 mg/kg twice daily. The dose was adjusted to keep trough levels of 100-200 mg/dl. This was continued for 6-12 months, after which the drug was tapered and finally stopped. Haploidentical HSCT were TCD using CliniMACS (Miltenyi Biotech, Bergisch-Gladbach, Germany) to o3 Â 10 4 CD3/kg. 
Supportive care
All patients were nursed in strict isolation in down-flow laminar facilities until engraftment. All blood products were CMV seronegative, leucodepleted and irradiated. All patients received regular antifungal (fluconazole/itraconazole), antiviral (aciclovir), anti-Pneumocystis carinii (cotrimoxazole) prophylaxis and regular immunoglobulin infusions for at least 3 months post-HSCT or until evidence of immune reconstitution, in the case of haploidentical grafts.
Engraftment
Chimerism analysis was performed using fluorescent in situ hybridization (FISH) techniques in sex-mismatched donorrecipient pairs and DNA polymorphism testing by PCR in sex-matched pairs.
Results
The conditioning regimen was well tolerated by all patients, with no specific conditioning-related toxicity (see Table 4 ).
Engraftment
Engraftment was defined as neutrophil count X0.5 Â 10 9 /l on 3 consecutive days. All patients (100%) engrafted within 14-21 days of HSCT (median 14 days, range 12-21 days). Patient 1 engrafted on day 14 and was completely donor chimeric on analysis. At 7 weeks post-HSCT, the level of donor chimerism fell to 95%. The patient was clinically well. Donor chimerism showed a further fall to 90% at 8 weeks. At 10 weeks post-HSCT, complete rejection occurred with autologous reconstitution and pancytopenia. The patient was retransplanted using the same donor 12 weeks after the initial HSCT. Conditioning was with fludarabine and methylprednisolone. The procedure was well tolerated. In all, 100% donor chimerism was documented 8 weeks post 2nd HSCT. On close monitoring, the patient started showing signs of rejection and her donor chimerism fell to 96%. She received two donor T-cell (CD3) infusions, 8 and 12 weeks after her 2nd HSCT, 1 Â 10 5 /kg and 5 Â 10 5 /kg T cells, respectively. She is now 54 months following her 2nd HSCT and clinically well with a normal full blood count. Her current donor chimerism is 98% and stable.
Patients 2, 4, 5, 6, and 7 all showed full engraftment and have remained 100% donor chimeric since the time of HSCT. They are 39, 37, 37, 33 and 13 months post-HSCT, respectively.
Patient 3 initially had two HSCT from his father as donor. This was a single antigen mismatch and was TCD. Unfortunately, he failed to engraft on both occasions. He then received a TCD haploidentical peripheral blood stem cell transplant (PBSCT) from his mother. He was conditioned with fludarabine and OKT3 for this HSCT. He engrafted on day 12 with 100% donor chimerism, but rejected 1 week later and became pancytopenic. He then received a fully matched unrelated cord blood transplant after being conditioned with fludarabine alone. He engrafted on day 14 and has been completely donor chimeric, clinically stable and well since. He is now 37 months following his last HSCT.
Rejection was seen in 2/9 (22%) patients. Both cases of rejection were seen in patients receiving TCD grafts and neither experienced any GVHD. All patients have evidence of full immune-reconstitution as measured by T, B and NK cell numbers and immunoglobulin levels.
Graft-versus-host disease
In seven of the nine (77%) HSCT GVHD was seen. Patient 1 did not have any GVHD during the 1st HSCT, but after the 2nd HSCT, developed grade II skin GVHD after receiving T-cell infusions. This was successfully treated with a short course of oral prednisolone. Patient 2 developed acute skin GVHD and was treated with oral steroids successfully. Patient 3 did not have any GVHD during his 1st HSCT but developed grade III-IV acute skin and gut GVHD, which progressed to chronic GVHD. He was treated with steroids and his immunosuppression was changed from cyclosporin to tacrolimus. The patient is now off all immunosuppression with no signs of GVHD. Patient 4 developed acute grade II skin and liver GVHD. She was treated with steroids and her immunosuppression was changed from cyclosporin to tacrolimus with good response. Patients 5 and 6 developed acute grade II skin GVHD, and responded well to steroids. At 10 months after HSCT, patient 6 had a flare up of skin GVHD and abnormal liver function tests, presumed to be liver GVHD. Immunosuppression was changed to tacrolimus with good response. Patient 7 had grade II skin GVHD, which responded to steroids and cyclosporin. Chronic GVHD occurred in 2/9 (22%).
Other complications
We did not observe any viral, fungal or PCP infections. Patient 2 had a number of post transplant complications. She developed portal vein thrombosis 15 weeks post-HSCT, for which she was treated with warfarin for 3 months. She then developed autoimmune haemolytic anaemia (AIHA), which was steroid dependant. She became grossly cushingoid and developed steroid-induced diabetes mellitus, needing insulin. She also developed osteoporosis secondary to long-term steroids, and is currently on bisphosphonates. She underwent splenectomy in an attempt to control her AIHA, but did not respond. She is currently on azathioprine. Patient 5 developed autoimmune thrombocytopenia, which responded to intravenous immunoglobulin. Patient 6 developed AIHA, which responded to steroids and cyclosporin. He also developed severe gastro-oesophageal reflux (GOR), which responded to prokinetic drugs. Patient 7 developed Evans syndrome, which was treated with intravenous steroids, immunoglobulins and rituximab. Full haematological response was achieved and the patient is recovering well. There was a high incidence of autoimmune cytopenias in this group of patients (4/7). This has been reported after nonmalignant transplants and reduced intensity regimens, but not to this extent. This is being further investigated (Table 4) .
Outcome
All seven children are alive after a median follow-up of 37 months (range 13-54 months). Patients 1, 3, 4 and 5 are well, haematologically stable, off all immunosuppression, 54, 36, 37 and 37 months after successful HSCT, respectively.
Patient 2 had problems with AIHA. She is presently haematologically stable on azathioprine. She is clinically well 39 months post-HSCT. Patient 6 developed chronic skin and possibly gut and liver GVHD, is off immunosuppression and steadily improving 33 months post-HSCT. Patient 7 developed Evans syndrome 3 months after HSCT and experienced an intracranial haemorrhage secondary to this. Full haematological recovery was seen after treatment and the patient is recovering well. All patients are fully immune reconstituted.
Discussion
Not all patients diagnosed with FA present with severe haematological disease. 22 Recently, IFAR presented data on disease progression in 388 FA patients. A total of 328 showed the characteristic congenital and/or haematological abnormalities, and 60 were siblings of probands. By 40 years of age, these patients carry an actuarial risk of 98% for cytopenia and 52% for MDS or AML. 2 Treatment for haematological disease in FA patients can either be supportive, that is, blood product transfusions, anabolic steroids, haematopoietic growth factors, or curative by HSCT. Clear-cut criteria concerning the timing of HSCT in FA patients do not exist, but it is the recommended treatment of choice for all patients with a suitable donor and life-threatening cytopenias.
Children with FA, with a matched family donor (MFD), and conditioned with a traditional regimen of low-dose CY (20 mg/kg) and thoraco-abdominal irradiation, generally engraft fully with few peritransplant complications. 3, 7, 23 These patients have been reported to have approximately 70% overall survival, 8% risk of rejection and 45% risk of developing acute and/or chronic GVHD. 3, 7, 23 For the remaining patients, results of transplantation from alternative donors have been reported to be less favourable, with graft rejection, regimen-related toxicity and GVHD being the greatest obstacles to successful outcome. 3, 4 In particular, for these patients, the 'ideal' preparative regimen capable of reducing the risk of organ toxicity, while ensuring a high level of engraftment and a low risk of GVHD, is still to be identified.
Fludarabine-based conditioning regimens, capable of intense T-cell immunosuppression, have been reported to lead to early, stable engraftment with minimal toxicity in patients with malignant or nonmalignant diseases. 18, 20 FA patients are natural candidates for reduced intensity HSCT using fludarabine-based conditioning regimens because of their cellular hypersensitivity to DNA crosslinking agents, and due to recent reports that the use of fludarabine in conditioning regimens in patients with FA transplanted from matched sibling donors is successful. 21, 24 All our patients had evidence of haematological disease with pancytopenia and trilineage involvement of the bone marrow. Owing to their young age, treatment with androgens was considered undesirable, because of the known side effects of this treatment. It was also felt that prolonged conservative treatment would only postpone curative therapy attempts, and therefore increase the risk of development of MDS or AML. Delay in HSCT may have led to the development of infectious complications or to allosensitization due to multiple transfusions. The absence of these complications in our patient group, their young age and stable disease are likely to have contributed to the favourable outcome. In this group of patients, engraftment was seen in 100%. Two patients (22%) showed rejection of TCD grafts, which was treated by a second successful graft in both patients. Complications and toxicity were uncommon. Acute GVHD occurred in 77% but was treatable with simple measures in all patients. Chronic GVHD was seen in two patients and has responded to treatment in both. All patients show full or stable donor chimerism at median follow-up of 32 months.
Of note in this cohort of patients is the exclusion of radiotherapy from the conditioning regimen. FA patients have been documented to be at high risk of developing solid tumours, such as squamous cell carcinoma years after HSCT. 25 Chronic GVHD and irradiation (total body or thoraco-abdominal) as part of the conditioning regimen are risk factors for the development of secondary tumours in patients with FA given an allograft. 25 Radiation itself has been recently reported to promote the development of chronic GVHD in children. 26 The use of a nonradiotherapy-based conditioning regimen is therefore attractive as it may have the advantage of reducing the risk of developing late malignancies in patients with FA surviving HSCT. Moreover, this type of preparative regimen could also prevent occurrence of growth impairment and sterility, well-known long-term side effects of irradiation. 27 The exclusion of radiotherapy did not appear to adversely affect the outcome of HSCT in this group of patients.
In conclusion, our data show that alternative donor transplantation in FA is possible. The use of a conditioning regimen without radiotherapy is also possible in FA even when using alternative donors. This regimen was associated with low toxicity and a rejection risk only when T-cell depletion was used. Alternative donors should be considered early in FA before transformation or significant exposure to blood products, both of which are likely to increase transplant-related mortality.
No definite conclusions can be drawn from this small number of patients, and more studies are needed to further investigate and confirm these findings.
